|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Morice P, Leary A, Creutzberg C,
Abu-Rustum N and Darai E: Endometrial cancer. Lancet.
387:1094–1108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ma J, Li D, Kong FF, Yang D, Yang H and Ma
XX: miR-302a-5p/367-3p-HMGA2 axis regulates malignant processes
during endometrial cancer development. J Exp Clin Cancer Res.
37:192018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen G, Zhang Y, Liang J, Li W, Zhu Y,
Zhang M, Wang C and Hou J: Deregulation of hexokinase II is
associated with glycolysis, autophagy, and the
epithelial-mesenchymal transition in tongue squamous cell carcinoma
under hypoxia. Biomed Res Int. 2018:84807622018.PubMed/NCBI
|
|
5
|
Chen G, Liu H, Zhang Y, Liang J, Zhu Y,
Zhang M, Yu D, Wang C and Hou J: Silencing PFKP inhibits
starvation-induced autophagy, glycolysis, and epithelial
mesenchymal transition in oral squamous cell carcinoma. Exp Cell
Res. 370:46–57. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee M and Yoon JH: Metabolic interplay
between glycolysis and mitochondrial oxidation: The reverse Warburg
effect and its therapeutic implication. World J Biol Chem.
6:148–161. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han J, Zhang L, Guo H, Wysham WZ, Roque
DR, Willson AK, Sheng X, Zhou C and Bae-Jump VL: Glucose promotes
cell proliferation, glucose uptake and invasion in endometrial
cancer cells via AMPK/mTOR/S6 and MAPK signaling. Gynecol Oncol.
138:668–675. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han X, Ren C, Yang T, Qiao P, Wang L,
Jiang A, Meng Y, Liu Z, Du Y and Yu Z: Negative regulation of
AMPKalpha1 by PIM2 promotes aerobic glycolysis and tumorigenesis in
endometrial cancer. Oncogene. 38:6537–6549. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ganapathy-Kanniappan S: Molecular
intricacies of aerobic glycolysis in cancer: Current insights into
the classic metabolic phenotype. Crit Rev Biochemi Mol Biol.
53:667–682. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mackay HJ, Eisenhauer EA, Kamel-Reid S,
Tsao M, Clarke B, Karakasis K, Werner HM, Trovik J, Akslen LA,
Salvesen HB, et al: Molecular determinants of outcome with
mammalian target of rapamycin inhibition in endometrial cancer.
Cancer. 120:603–610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gehrig PA, Le LV, Olatidoye B and Geradts
J: Estrogen receptor status, determined by immunohistochemistry, as
a predictor of the recurrence of stage I endometrial carcinoma.
Cancer. 86:2083–2089. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Myers AP: New strategies in endometrial
cancer: Targeting the PI3K/mTOR pathway-the devil is in the
details. Clin Cancer Res. 19:5264–5274. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li LH, Zhang PR, Cai PY and Li ZC: Histone
deacetylase inhibitor, romidepsin (FK228) inhibits endometrial
cancer cell growth through augmentation of p53-p21 pathway. Biomed
Pharmacother. 82:161–166. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
De U, Son JY, Sachan R, Park YJ, Kang D,
Yoon K, Lee BM, Kim IS, Moon HR and Kim HS: A new synthetic histone
deacetylase inhibitor, MHY2256, induces apoptosis and autophagy
cell death in endometrial cancer cells via p53 acetylation. Int J
Mol Sci. 19:27432018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zheng Y and Yang X, Wang C, Zhang S, Wang
Z, Li M, Wang Y, Wang X and Yang X: HDAC6, modulated by miR-206,
promotes endometrial cancer progression through the PTEN/AKT/mTOR
pathway. Sci Rep. 10:35762020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weichert W: HDAC expression and clinical
prognosis in human malignancies. Cancer Lett. 280:168–176. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Senese S, Zaragoza K, Minardi S, Muradore
I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser
C and Chiocca S: Role for histone deacetylase 1 in human tumor cell
proliferation. Mol Cell Biol. 27:4784–4795. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang Z, Ding S, Huang H, Luo P, Qing B,
Zhang S and Tang R: HDAC1 triggers the proliferation and migration
of breast cancer cells via upregulation of interleukin-8. Biol
Chem. 398:1347–1356. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao LL, Song X, Pei L, Liu L, Wang H and
Jia M: Histone deacetylase HDAC1 expression correlates with the
progression and prognosis of lung cancer: A meta-analysis. Medicine
(Baltimore). 96:e76632017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu X, Yu Y, Zhang J, Lu C, Wang L, Liu P
and Song H: HDAC1 silencing in ovarian cancer enhances the
chemotherapy response. Cell Physiol Biochem. 48:1505–1518. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cao LL, Yue Z, Liu L, Pei L, Yin Y, Qin L,
Zhao J, Liu H, Wang H and Jia M: The expression of histone
deacetylase HDAC1 correlates with the progression and prognosis of
gastrointestinal malignancy. Oncotarget. 8:39241–39253. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weichert W, Roske A, Niesporek S, Noske A,
Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T and Denkert
C: Class I histone deacetylase expression has independent
prognostic impact in human colorectal cancer: Specific role of
class I histone deacetylases in vitro and in vivo. Clin Cancer Res.
14:1669–1677. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Prat J: FIGO staging for uterine sarcomas.
Int J Gynaecol Obstet. 104:177–178. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li L, Liang Y, Kang L, Liu Y, Gao S, Chen
S, Li Y, You W, Dong Q, Hong T, et al: Transcriptional regulation
of the Warburg effect in cancer by SIX1. Cancer Cell. 33:368–385.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu F, Gu LN, Shan BE, Geng CZ and Sang
MX: Biomarkers for EMT and MET in breast cancer: An update. Oncol
Lett. 12:4869–4876. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nantajit D, Lin D and Li JJ: The network
of epithelial-mesenchymal transition: Potential new targets for
tumor resistance. J Cancer Res Clin Oncol. 141:1697–1713. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang XJ and Seto E: HATs and HDACs: From
structure, function and regulation to novel strategies for therapy
and prevention. Oncogene. 26:5310–5318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Villagra A, Sotomayor EM and Seto E:
Histone deacetylases and the immunological network: Implications in
cancer and inflammation. Oncogene. 29:157–173. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Glozak MA and Seto E: Histone deacetylases
and cancer. Oncogene. 26:5420–5432. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stazi G, Fioravanti R, Mai A, Mattevi A
and Valente S: Histone deacetylases as an epigenetic pillar for the
development of hybrid inhibitors in cancer. Curr Opin Chem Biol.
50:89–100. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Garmpis N, Damaskos C, Garmpi A, Spartalis
E, Kalampokas E, Kalampokas T, Margonis GA, Schizas D, Andreatos N,
Angelou A, et al: Targeting histone deacetylases in endometrial
cancer: A paradigm-shifting therapeutic strategy? Eur Rev Med
Pharmacol Sci. 22:950–960. 2018.PubMed/NCBI
|
|
33
|
Khabele D, Son DS, Parl AK, Goldberg GL,
Augenlicht LH, Mariadason JM and Rice VM: Drug-induced inactivation
or gene silencing of class I histone deacetylases suppresses
ovarian cancer cell growth: Implications for therapy. Cancer Biol
Ther. 6:795–801. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin CL, Tsai ML, Lin CY, Hsu KW, Hsieh WS,
Chi WM, Huang LC and Lee CH: HDAC1 and HDAC2 double knockout
triggers cell apoptosis in advanced thyroid cancer. Int J Mol Sci.
20:4542019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang L, Bu L, Hu J, Xu Z, Ruan L, Fang Y
and Wang P: HDAC1 knockdown inhibits invasion and induces apoptosis
in non-small cell lung cancer cells. Biol Chem. 399:603–610. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ji M, Lee EJ, Kim KB, Kim Y, Sung R, Lee
SJ, Kim DS and Park SM: HDAC inhibitors induce
epithelial-mesenchymal transition in colon carcinoma cells. Oncol
Rep. 33:2299–2308. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Feng J, Cen J, Li J, Zhao R, Zhu C, Wang
Z, Xie J and Tang W: Histone deacetylase inhibitor valproic acid
(VPA) promotes the epithelial mesenchymal transition of colorectal
cancer cells via up regulation of snail. Cell Adh Migr. 9:495–501.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jakobsen KR, Demuth C, Sorensen BS and
Nielsen AL: The role of epithelial to mesenchymal transition in
resistance to epidermal growth factor receptor tyrosine kinase
inhibitors in non-small cell lung cancer. Transl Lung Cancer Res.
5:172–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sakamoto T, Kobayashi S, Yamada D, Nagano
H, Tomokuni A, Tomimaru Y, Noda T, Gotoh K, Asaoka T, Wada H, et
al: A histone deacetylase inhibitor suppresses
epithelial-mesenchymal transition and attenuates chemoresistance in
biliary tract cancer. PLoS One. 11:e01459852016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ruscetti M, Dadashian EL, Guo W, Quach B,
Mulholland DJ, Park JW, Tran LM, Kobayashi N, Bianchi-Frias D, Xing
Y, et al: HDAC inhibition impedes epithelial-mesenchymal plasticity
and suppresses metastatic, castration-resistant prostate cancer.
Oncogene. 35:3781–3795. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bruzzese F, Leone A, Rocco M, Carbone C,
Piro G, Caraglia M, Gennaro ED and Budillon A: HDAC inhibitor
vorinostat enhances the antitumor effect of gefitinib in squamous
cell carcinoma of head and neck by modulating ErbB receptor
expression and reverting EMT. J Cell Physiol. 226:2378–2390. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lunt SY and Heiden MG: Aerobic glycolysis:
Meeting the metabolic requirements of cell proliferation. Ann Rev
Cell Dev Biol. 27:441–464. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen C, Wei M, Wang C, Sun D, Liu P, Zhong
X, He Q and Yu W: The histone deacetylase HDAC1 activates
HIF1α/VEGFA signal pathway in colorectal cancer. Gene.
754:1448512020. View Article : Google Scholar : PubMed/NCBI
|
